Nicolle G, Daher A, Maillé P, Vermey M, Loric S, Bakkar A, Wallerand H, Vordos D, Vacherot F, de Medina S, Abbou C, Van der Kwast T, Thiery J, Radvanyi F, Chopin D. Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. Clinical cancer research : an official journal of the American Association for Cancer Research 12 (9) , 2937-43 (2006) PubMed ID:(16675591)

Bakkar A, Quach V, Le Borgne A, Toublanc M, Henin D, Wallerand H, Radvanyi F, Bittard H, Ravery V, Gibod L, de Medina S, Chopin D, Grandchamp B. Sensitive allele-specific PCR assay able to detect FGFR3 mutations in tumors and urine from patients with urothelial cell carcinoma of the bladder. Clinical chemistry 51 (8) , 1555-7 (2005) PubMed ID:(16040860)

Wallerand H, Bakkar A, de Medina S, Pairon J, Yang Y, Vordos D, Bittard H, Fauconnet S, Kouyoumdjian J, Jaurand M, Zhang Z, Radvanyi F, Thiery J, Chopin D. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis 26 (1) , 177-84 (2005) (Epub 03 Sep 2004) PubMed ID:(15347601)

Bakkar A, Wallerand H, Radvanyi F, Lahaye J, Pissard S, Lecerf L, Kouyoumdjian J, Abbou C, Pairon J, Jaurand M, Thiery J, Chopin D, de Medina S. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer research 63 (23) , 8108-12 (2003) PubMed ID:(14678961)